Lifebit, a leading provider of genomics and health data software, has made a significant move into the Asia Pacific and Japan (APJ) region with the establishment of its new regional operation headquartered in Singapore. This expansion marks a strategic collaboration with Synapxe, Singapore’s national HealthTech agency, aiming to propel precision medicine initiatives across the APJ region. By leveraging Lifebit’s patented federated technology platform for genomics and biomedical data, the partnership seeks to support vital precision medicine research in the region.
Driving Precision Medicine in Singapore and Beyond
Singapore has emerged as a key market in Asia, driven by a strong governmental commitment to advancing precision medicine research and innovation through the utilization of genomic and clinical data. Lifebit’s decision to set up an R&D center in Singapore underscores its dedication to contributing to the region’s precision medicine landscape. With a diverse population facing significant health challenges, Singapore presents a crucial milestone for Lifebit’s mission.
Empowering Biomedical Research Globally
Lifebit’s overarching goal is to eliminate barriers to accessing biomedical data, facilitating advancements in disease treatment and prevention. The company’s expansion into APJ builds upon its recent growth and partnerships established in the USA, Central and South America, and Europe over the past year. Bolstered by a $60 million Series B funding round in 2022 led by Tiger Global Management, Lifebit continues to pioneer technology that enhances the accessibility and usability of biomedical data.
Enabling Faster Insights and Discoveries
Lifebit’s suite of AI-powered federated software solutions offers a secure research environment for unlocking insights from biomedical data. By streamlining data analysis processes, Lifebit’s technology accelerates drug discovery pipelines, enhances clinical trial interpretation, and ultimately fosters breakthroughs in medical research.
